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Abstract
Bacground/Aim. Prediction and prevention of preterm deliv-
ery remain great challenge. It is important to include in everyday
medical practice determination of certain markers that could
help identifying pregnant women with preterm delivery. Insulin-
like growth factor (IGF) is involved in the control mechanism
of fetal and placental growth and development. The aim of this
study was to examine the presence of insulin-like growth factor
binding protein 1 (IGFBP-1) in cervicovaginal secretion of
pregnant women with symptoms of preterm labor, but with ap-
parently intact fetal membranes and to point out a possibile ap-
plication of the strip test for detection of phIGFBP-1 in diagno-
sis of preterm premature rupture of total membrans (PPROM)
in everyday medical practice. Methods.  The study was per-
formed at the Department for Obstetrics and Gynecology,
Clinical Center of Vojvodina between October 2008 and May
2009. The study included 54 pregnant women between 20–35
weeks of gestation (WG), divided into two groups: the study
group (16 pregnant women with symptoms of preterm delivery
that gave birth before 37 WG) and the control group (38 preg-
nant women with the normal course of pregnancy that gave
birth on term). In cervicovaginal secretion of the examined
pregnant women the level of IGFBP-1 was determined by the
immunochromatographic assay with monoclonal antibodies
6303 as a detecting antibody (Actim PROM test, Medix Bio-
chemica, Kauniainen, Finland). Results. Gestational age (GA)
at delivery in the study group was 32.6 WG and in the control
group it was 38.4 WG. Weight of newborns in the study group
was 2,021 g and in the control group 3,430 g. IGFBP test was
positive in 15 women (93.75%) of the study group, while in the
control group it was positive only in 1 woman (2.63%). Con-
clusion. Test on phIGFBP-1 in cervicovaginal mucus was
positive in 93.75% women with preterm delivery, suggesting
that this test could be used in diagnosis of silent rupture of fetal
membranes and in prediction of preterm delivery.
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Apstrakt
Uvod/Cilj.  Predikcija i prevencija prevremenog porođaja
predstavlja veliki izazov i zato bi bilo veoma važno da se u
svakodnevnu praksu uvedu markeri koji bi pomogli u pre-
poznavanju ovih trudnica. Faktor rasta sličan insulinu
(IGFBP-1) uključen je u kontrolni mehanizam fetusnog i
placentarnog rasta i razvoja. Cilj rada bio je ispitivanje prisu-
stva vezujućeg proteina-1 za faktor rasta sličan insulinu
(IGFBP-1) u cervikovaginalnom sekretu žena sa simptomi-
ma prevremenog porođaja, ali sa naizgled intaktnim fetalnim
membranama i ukazivanje na mogućnost primene testa na
phIGFBP-1 u dijagnostici preterminske prematurne rupture
(PPROM) fetusnih membrana u svakodnevnoj praksi. Me-
tode. Istraživanje je sprovedeno na Klinici za ginekologiju i
akušerstvo Kliničkog centra Vojvodine u periodu od oktob-
ra 2008. do maja 2009. godine. Istraživanjem su bile obu-
hvaćene 54 trudnice između 20 i 35 nedelja gestacije (NG),
podeljene dve grupe: ispitivanu (16 trudnica sa simptomima
prevremenog porođaja koje su se porodile pre 37 NG) i
kontrolnu (38 trudnica sa urednim tokom trudnoće koje su
porođene u terminu). U cervikovaginalnom sekretu ispitiva-
nih trudnica određena je koncentracija phIGFBP-1 imuno-
hromatografskom metodom sa monoklonalnim antitelima
6 303 koji vezuju phIGFBP-1. Rezultati. Pri porođaju ges-
tacijska starost u ispitivanoj grupi bila je 32,6 NG, a u kon-
trolnoj 38,4 NG. Telesna masa novorođenčadi u ispitivanoj
grupi iznosila je 2 021 g, dok je u kontrolnoj iznosila 3 430
g. Pozitivan phIGFBP-1 u ispitivanoj grupi imalo je 15
(93,75%) trudnica, a u kontrolnoj grupi jedna (2,63%). Za-
ključak. Kod 93,75% trudnica čija trudnoća se završila pre-
vremenim porođajem, test na phIGFBP-1 u cervikovaginal-
nom mukusu bio je pozitivan, što ukazuje na mogućnost
primene ovog testa u dijagnostikovanju prikrivenih ruptura
plodovih ovojaka i u predviđanju prevremenog porođaja.
Ključne reči:
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Introduction
Prediction and prevention of preterm delivery remain
great challenge in obstetrics. Therefore, it would be very im-
portant to point out a possible application in everyday medi-
cal practice of certain markers that could help in identifying
pregnant women with a silent preterm premature rupture
(PPROM) of fetal membranes, who have the highest risk of
preterm delivery and who might benefit from timely admis-
sion and appropriate treatment.
The insulin-like growth factor (IGF) (including IGF-I
and IGF-II, their receptors and the binding proteins) is in-
volved in the control mechanism of fetal and placental growth
and development. The insulin-like growth factor binding pro-
tein 1 (IGFBP-1) is mainly secreted by the fetal and adult liver.
Its concentraction in maternal plasma increases as pregnancy
advances. It is a major constituent of amniotic fluid from the
second trimester to term. Concentration of IGFBP-1 in amni-
otic fluid is 100–1,000 fold higher than in the serum. Amniotic
fluid contains non-phosphorylated and less phosphorylated
isoforms of IGFBP-1, whereas the decidua contains phospho-
rylated isoforms, including a highly phosphorylated isoform
(phIGFBP-1) not present in amniotic fluid 
1–5. Because of this
difference, the origin of IGFBP-1, decidua or amniotic fluid
isoforms of IGFBP-1 can be identified through the use of
monoclonal antibodies. The presence of amniotic fluid iso-
forms of IGFBP-1 in cervical samples has proved to be diag-
nostic as regards rupture of fetal membranes (Actim PROM
test, Medix Biochemica, Kauniainen, Finland) and testing is
currently in routine use 
1, 6–10.
The aim of this study was to examine the presence of
highly phosphorylated isoform (decidual) of the insulin-like
growth factor binding protein 1 (phIGFBP-1) in cervicovagi-
nal secretion of pregnant women with symptoms of preterm
labor, but with apparently intact fetal membranes, as well as
to point out a possibile application of the strip test for detec-
tion of phIGFBP-1 (Actim PROM test, Medix Biochemica,
Kauniainen, Finland) in everyday medical practice for diag-
nosis of increased risk of preterm delivery.
Methods
The study was performed at the Department of Obstet-
rics and Gynecology, Clinical Center of Vojvodina between
October 2008 and May 2009. The protocol for this study was
performed in compliance with the Decleration of Helsinki
from 1975, which was revised in 1983, and approved by the
Etichal Committee of Clinical Center of Vojvodina (Novi
Sad). The investigation included 54 pregnant women be-
tween 20 and 35 weeks gestation (WG). Gestational age was
based on the last menstrual period and was confirmed by
early first trimestar ultrasonography. A total of 16 women
with symptoms of preterm delivery (presence of contractions
or increased tonus of the uterus, but without cervical changes
or an evident rupture of membranes) who delivered prema-
turely (before 37 WG) were enrolled into the study group.
The control group (n = 38) included pregnant women with-
out symptoms of preterm delivery, who delivered in term
(37–40 WG). Anamnestic data were taken from all patients
and obstetrical examination was performed. The concentra-
tion of  phIGFBP-1 in cervicovaginal secretion of investi-
gated pregnant women was measured by immunochromato-
graphic assay with monoclonal antibodies 6 303 as a detect-
ing antibody (Actim PROM test, Medix Biochemica,
Kauniainen, Finland).
The pregnant women with positive results of Actim
PROM test were treated with antibiotics from the cephalo-
sporine or penicillin groups to prevent infection, and with
dexametason (6 mg four times per day in duration of 48 h)
for fetal lung maturation.
The Student’s t-test was used for statistical analysis.
Any p-value less than 0.05 was considered significant.
Results and discussion
Table 1 shows maternal demographic characteristics
(age, information about previous deliveries as well as spon-
taneous abortions and preterm deliveries) in both the study
and the control groups. Maternal age was between 20 and 38
years in both groups (approximately 29.8 years in the study
group and 29.3 years in the control group). Previous preterm
deliveries had 6.25% women from the study group and
5.26% women from the control group. Previous spontaneous
abortions had 25% women from the study group and 7.89%
from the control group.
Table 2 shows obstetric parameters in both investigated
groups. The mean GA of pregnant women at the moment
Actim PROM test was performed, was 28.2 WG in the study
group and 30.3 WG in the control group, while cervical
dilatation was 1.9 cm in the study group, and 1.0 cm in the
control group. The mean GA at birth was 32.5 WG in the
study group and 38.4 WG in the control group.
Table 1
Demographic characteristics of pregnant women
Characteristics Study group Control group
Age (years), ґ ± SD 29.75 ± 4.64 29.29 ± 3.59
Gravidy (n), ґ ± SD 2.13 ± 1.45 1.58 ± 0.64
Parity (n), ґ ± SD 1.75 ± 1.06 1.5  ± 0.6
Previous preterm deliveries (%) 6.25 5.26
Previous spontaneous abortions (%) 25 7.89
Study group – preterm delivery
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The modus of delivery is shown in Figure 1. Vaginal
delivery had 56.25% women from the study group and
81.58% women from the control group. Cesarean section
was performed in 43.75% women in the study group, and in
18.42% women in the control group. No postpartum and
postoperative complications were noted in the mothers of
both groups.
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Fig. 1 – The way of the delivery termination
Control group – term delivery
Study group – preterm delivery
The results of Actim PROM test are presented in Fig-
ure 2. Positive test for phIGFBP-1 had 15 (93.75%) pa-
tients in the study group, and only 1 (2.63%) in the control
group (p < 0.05).
In both groups there were 53 live birhts and one stealbirth
(in the study group). Average body weight of the infants in the
study group was 2,021 g, and in the control group 3,430 g.
Preterm premature rupture of fetal membrans is very
frequent diagnostic and therapeutic dilemma in obstetrics.
The tests previously used for diagnosis of PPROM (the use
of litmus paper or nitrazine swabs for detection of vaginal
pH, the vaginal prolactin test, tests for alpha-fetoprotein and
vaginal fibronectin) are insufficient and frequently give false
positive results because of the presence of blood or semen in
cervical mucus and vagina.
The Actim PROM test is superior in comparison with
the tests mentioned above because it does not react with
mucus, blood or semen, and sensitivity of the test is so high
that even micro ruptures of fetal membranes can be de-
tected 
11–18.
The obtained results suggest that 93.75% pregnant
women who delivered prematurely (the study group) also
had preterm rupture of fetal membranes (positive test for
phIGFBP-1 in cervical mucus). This indicates the possibility
of using this test in diagnosis of micro ruptures of fetal
membranes. Since the test is very simple and gives a result in
a few minutes, it is possible to prescribe antibiotics and cor-
ticosteroid therapy for pregnant women in the nick time and
to prolong their pregnancy, as well as to suppress infection
and avoid respiratory distress in newborns.
Conclusion
Our results suggest that IGFBP-1 test could be used in
diagnosis of silent rupture of fetal membrans and in predic-
tion of preterm delivery.
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Table 2
Obstetric parameters in pregnant women
Obstetric parameters Study group
ґ ± SD
Control group
ґ ± SD
Gestational age at admission (weeks) 28.19 ± 6.39 30.32 ± 4.81
Gestational age at delivery (weeks) 32.56 ± 2.53 38.38 ± 1.13
Cervix dilatation in the moment of hospitalization (cm) 1.88 ± 1.23 0.99 ± 0.84
Study group – preterm delivery
Control group – term delivery
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Fig. 2 – Test results on the presence of phIGFBP-1 in cervical mucus of pregnant women
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